Logotype for Cardiol Therapeutics Inc

Cardiol Therapeutics (CRDL) investor relations material

Cardiol Therapeutics Study Result summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Cardiol Therapeutics Inc
Study Result summary1 Dec, 2025

Study Overview and Objectives

  • ARCHER was a phase II, multi-center, randomized, double-blind, placebo-controlled trial evaluating Cardiol Rx in acute myocarditis, enrolling 109 patients across 34 centers globally, with an average age of 39 and predominantly male participants.

  • The study focused on cardiac MRI endpoints predictive of prognosis, including extracellular volume (ECV), intracellular volume (ICV), left ventricular (LV) mass, and functional and volumetric cardiac parameters.

  • Most patients had preserved LV function at baseline, presented with chest pain and elevated troponin, and were hospitalized for acute myocarditis.

  • Cardiol Rx is a high-concentration cannabidiol oral solution targeting inflammasome activation, with a next-generation subcutaneous formulation (CRD38) in development for chronic heart conditions.

  • The trial was designed and overseen by an international steering committee of myocarditis and heart failure experts, and results were presented at the European Society of Cardiology Working Group meeting.

Key Results and Clinical Insights

  • Cardiol Rx led to a notable reduction in ECV (3.7 ml), ICV (5.6 ml), and LV mass (over 9 grams), indicating decreased myocardial inflammation and edema, with improvements in cardiac structure and chamber volumes.

  • The magnitude of LV mass reduction is comparable to effects seen with established therapies for heart failure and hypertension.

  • Cardiol Rx was safe and well tolerated, with balanced adverse event rates and no new safety signals identified.

  • The findings provide clinical proof of concept for Cardiol Rx in treating inflammation-driven cardiac damage and support further development of CRD38.

  • Chronic inflammation is a key driver of adverse cardiac remodeling, and Cardiol Rx directly targets this biology.

Expert Perspectives and Future Directions

  • Experts highlighted ARCHER as the first study to show structural cardiac improvement with a therapeutic intervention in myocarditis.

  • The reduction in LV mass supports the hypothesis that targeted therapy can remodel the heart by addressing inflammation and edema early in myocarditis.

  • There is enthusiasm for expanding research into more severe myocarditis, heart failure with preserved ejection fraction, and checkpoint inhibitor myocarditis.

  • The results strengthen confidence in the ongoing phase III MAVERICK trial in recurrent pericarditis and support broader development in inflammatory heart disease.

  • The company is accelerating IND-enabling work for CRD38 and exploring partnerships for broader heart failure indications.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Cardiol Therapeutics earnings date

Logotype for Cardiol Therapeutics Inc
Q4 202527 Mar, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Cardiol Therapeutics earnings date

Logotype for Cardiol Therapeutics Inc
Q4 202527 Mar, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Cardiol Therapeutics Inc. is a biopharmaceutical company focused on developing anti-inflammatory and anti-fibrotic therapies for cardiovascular diseases. The company specializes in small molecule therapeutics targeting conditions such as acute myocarditis, heart failure, and other inflammatory heart disorders. The company is headquartered in Oakville, Ontario, Canada, and its shares are listed on the NASDAQ and TSX.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage